Dr. LaxmiShrikhande
MD;FICOG;FICMU
Director-Shrikhande Fertility Clinic, Nagpur
President Menopause Society, Nagpur
National Corresponding Editor-The Journal of Obstetrics & Gynecology of India
Senior Vice President FOGSI 2012
Vice Chairperson Indian College OB /GY
Governing Council member ICOG 2012-2017
Governing Council Member ISAR 2014-2019
Governing Council Member IAGE for 3 terms
Patron-Vidarbha Chapter ISOPARB
Chairperson-HIV/AIDS Committee, FOGSI (2007-09)
Received Best Committee Award of FOGSI
Received Bharat excellence Award for women’s health
President Nagpur OB/GY Society 2005-06
Associate member of RCOG
Member of European Society of Human Reproduction
Visited 96 FOGSI Societies as invited faculty
Delivered 3 orations
Publications-Thirteen National & seven International
Presented Papers in FIGO, AICOG, SAFOG, AICC-RCOG conferences
Conducted adolescent health programme for more than 15,000 adolescent girls
Recurrent Pregnancy loss
DR LAXMI SHRIKHANDE
NAGPUR
Introduction
Emotionally traumatic, similar to stillbirth or neonatal death
Primary / secondary / Tertiary
Primary RPL- refers to multiple losses in a woman with no previous viable infants,
secondary RPL refers to multiple losses in a woman who has already had a pregnancy beyond 20
gestational weeks
Tertiary RPL refers to multiple pregnancy losses between normal pregnancies
◦Better prognosis with secondary and Tertiary
Terminology for pregnancy loss prior to viability : a consensus statement from the ESHRE early pregnancy special interest group.
Hum Reprod 2015;30(3):495-498
Nomenclature for pregnancy outcomes : time for a change. Obstet Gynecol 2011 ; 118(6): 1402-1408
RPL – basic facts
1% of women have recurrent miscarriages
A majority of women do not have an identifiable cause
At least 70% of women have a successful pregnancy
outcome in the subsequent pregnancy
ACOG Practice Bulletin No.24, 2001
RCOG GreenTop Guideline No.17, 2003
Why is studying RPL difficult?
More than one factor may exist in the same couple
Lacunae in literature
◦ Differences in definitions, evaluation protocols
◦ Variations in treatment regimens even with the same drug
◦ Randomized trials need to be very large to prove statistical and
clinically significant differences
Women with H/O 2 previous spontaneous abortions
Has come for preconception counselling
Will you start investigating ?
Recurrent Miscarriage
Recurrent Miscarriage Definitions
◦ 3 or more consecutive pregnancy losses (UK)1
◦ 2 or more consecutive pregnancy losses (USA)2
◦ Miscarriage as loss of fetus weighing ≤ 500g, which would
normally be at 20-22 complete weeks of gestation (WHO)3
1. Royal College of Obstetricians and Gynaecologists 2011. The Investigation and Treatment of Couples with
Recurrent First-trimester and Second-trimester Miscarriage, [Guideline no. 17]. London, UK.
2. 2. Practice Committee of the American Society for Reproductive Medicine. Fertil Steril 2008; 90(5 Suppl): S60.
3. 3. Pokale YS. Int. Res. J. Medical Sci. 2015;3(9):13-19
How you will proceed further ?
Diagnostic Work-Up in Recurrent
Miscarriage?
Pathogenesis & Diagnostic Work-Up in Recurrent Miscarriage (RM)
Heterogeneous condition
Pathogenesis is multifactorial, complex and poorly
understood
Standard investigative protocol fails to identify
specific cause in 50% of cases
Walch KT & Huber JC. Best Practice & Research Clinical Obstetrics and Gynaecology. 2008; Vol. 22, No. 2, pp. 375–389. Pokale YS. Int. Res. J.
Medical Sci. 2015;3(9):13-19
What are the possible causes of RPL
Possible Causes of Miscarriage
Paternal Factor
Abnormal embryo
 Structural anomalies incompatible with life1
 Chromosomal abnormalities: trisomy, polyploidy, monosomy X, structural abnormalities
of individual chromosomes2
Hostile maternal environment
 Uterine abnormalities: congenital anomalies, adhesions, leiomyoma2
 Infection: bacterial vaginosis, toxoplasmosis, listeriosis, chlamydia, gonorrhea, rubella2
 Chronic maternal disease: poorly controlled diabetes, celiac disease2
 Immune dysfunction: antiphospholipid antibody syndrome2 and thyroid autoimmunity1
 Endocrine: failure of proper progesterone concentration, thyroid hormone levels3
1. Larsen EC et al. BMC Medicine 2013; 11: 154-65. 2. Griebel CP et al. Am Fam Physician 2005;1; 72(7): 1243-50.3. Zhang HX et al. Clin Exp Obstet Gynecol 2014; 41(2): 182-5.
Etiology
Established causes of recurrent miscarriage include
 immunological (20-50%),
endocrine (17-20%),
anatomical (12-16%),
genetic (5%), and
infection (0.5-1.5%).
Evaluation
It includes taking
history,
physical examination and
appropriate investigations which differ with the trimester though there is an
overlap.1
1) Evaluation and management of recurrent early pregnancy loss.
Stephenson M, Kutteh W.Clin Obstet Gynecol. 2007 Mar;50(1):132-45.
History
Gestational age of the loss. Chromosomal & endocrine earlier than anatomic or immunological causes
Irregular menstrual cycles or galactorrhoea suggestive of possible Endocrine dysfunction/ Hyperprolactinemia
Consanguinity/ family h/o congenital abnormalities/early losses - Genetic
Uterine instrumentation- possible intrauterine adhesions
Exposure to exogenous agents like bisphenol A and concurrent noxious agents is difficult to recall, document and
to measure the toxin dose.
Radiation and Chemotherapeutic agents, chemicals.
Alcohol and caffeine intake are toxic to the embryo in a dose-dependent manner.
Cigarette smoking,
H/o thrombosis - APLA
PCOS
Information from previous laboratory, pathology, and imaging studies
Examination
General-Signs of endocrinopathy (hirsutism, galactorrhea, thyroid)
Systemic
Gynec
TVS
Which tests to order ?
Eyes can’t see what mind doesn’t know
From History and examination you should draw your further course of action
Investigations recommended for recurrent miscarriages
Investigation Recommendation If required
Genetic - Karyotype Parental and fetal
Anatomical Two-dimensional/
three-dimensional
ultrasonography and
sonohysterography
Hysteroscopy, laparoscopy, or
magnetic resonance imaging
Thrombophilia Acquired APS Inherited
Infection Chlamydia, Endometrial
biopsy and culture
Immunological Antinuclear antibody
Endocrine Thyroid -TSH, Antibodies Prolactin,HbA1C
Male factor Sperm DNA fragmentation
index
Male factor-
Some studies suggest that DNA fragmentation is increased with RPL,
especially in the in vitro fertilization setting.
The ASRM guidelines state that routine sperm DNA fragmentation
indexing is not indicated because of the weak evidence, but
 the ESHRE guidelines state that this can be done to provide an
explanation for RPL.
Evidence
Further compelling reasons for testing sperm DNA come from its strong
associations with miscarriage.
A systematic review and meta-analysis (16) of 16 cohort studies (2969 couples),
14 of which were prospective studies which examined the effect of sperm DNA
damage on miscarriage rates was performed.
The meta-analysis showed a significant increase in miscarriage in patients with
high DNA damage compared with those with low DNA damage
(Risk Ratio (RR)= 2.16 [1.54, 3.03], P <0.00001).
Recurrent Miscarriage-Maternal causes
Recommended Investigations to Search for Causes (UK)1
1. Royal College of Obstetricians and Gynaecologists 2011. The Investigation and Treatment of Couples with
Recurrent First-trimester and Second-trimester Miscarriage, [Guideline no. 17]. London, UK.
Antiphospholipid antibodies Karyotyping
Anatomical factors Thrombophilias
Antiphospholipid Antibody Syndrome
and
RPL
A number of antibodies have been studied
The antibodies with the greatest significance and association with
obstetric events are
Lupus anticoagulant (LA)
Anticardiolipin antibodies (ACL IgG and ACL IgM)
Others such as β2glycoprotein-I, antiphosphatidylserine antibodies,
annexin, etc may not be obstetrically significant
Which antibodies ?
•5 – 20% of women with recurrent miscarriages have antiphospholipid
antibodies
MacLean AS et al, BJOG 1994
Rai RS et al, Hum Reproduction 1995
Balasch J et al, Hum Reproduction 1996
Incidence
How you will diagnose APS ?
•Based on clinical and laboratory criteria
•One obstetric or thrombotic criteria and one laboratory criteria should be
present to diagnose PAPS
•Other autoimmune disease has to be ruled out to make the diagnosis of PAPS
Wilson A et al, International Consensus statement on APS,
Arthritis Rheumatol 1999
Diagnosis of PAPS
Three or more consecutive spontaneous abortion before
the 10th week of gestation
One or more unexplained fetal death at or beyond the 10th
week of gestation
Severe preeclampsia or placental insufficiency (IUGR)
necessitating birth before the 34th week of gestation
Obstetric Criteria
•Anticardiolipin antibody IgG or IgM isotype in medium to high titers
by standardized ELISA assay
•Lupus anticoagulant present
•A positive test has to be repeated on at least one more occasion six
weeks apart to fulfill the laboratory criteria
Laboratory Criteria
Usually an over diagnosed syndrome
Not meeting clinical and the strict laboratory criteria
Not repeating the laboratory test at 6 weeks
Non standardized ELISA for ACL antibodies
Inter laboratory variations for phospholipid dependent coagulation
tests used for screening for lupus anticoagulant
Pitfalls in diagnosis of PAPS
Improperly collected and processed samples
Temporal and trimester wise fluctuations
VDRL positive patients who may or may not have syphilis
General infections and inflammations
Coagulopathies and anticoagulant medication users (including
aspirin, heparin)
False results in PAPS
How to treat ?
Avoid early pregnancy loss
Normalize placental and fetal circulations to prevent early
birth from obstetric complications such as preeclampsia and
growth restriction
Prevent maternal vascular thrombosis in pregnancy and
postpartum
Goals for treating PAPS
Women with PAPS
without a history of
thrombotic events
(most women with RPL)
Women with PAPS with
history of thrombotic
events (past or present)
Prophylactic therapies
such as aspirin, heparin in
pregnancy and 6 to 8
weeks postpartum
Full anticoagulation with
heparin (or warfarin) in
pregnancy and postpartum
Recent meta analysis shows that the combination of
Aspirin + Heparin is better than Aspirin alone in
achieving live births in women with recurrent
pregnancy loss and antiphospholipid antibodies
Aspirin alone v/s Aspirin + Heparin
Mak A et al, Rheumatology (Oxford) 2010
How to use heparin ?
•There is controversy as to whether LMW Heparin is effective in
preventing recurrent pregnancy loss
•Consider costs, convenience and compliance before initiating
therapy
•Therapy should be started when fetal cardiac activity is
demonstrated and continued throughout pregnancy and postpartum
•Heparin in prophylactic doses needs to be stopped for about 24
hours around the time of labor and delivery
Clinical Tips for using Heparin
Heparin in prophylactic doses should not be monitored and does
not require monitoring by coagulation parameters
Do a platelet count at 3 days, 1 week and bimonthly when the
patient is on heparin
Standard doses
Unfractionated heparin – 5000 units sc bd
Enoxaparin – 40 mg sc daily or in two doses
Clinical Tips for using Heparin
What not to do for PAPS
•Steroid therapy should be avoided for PAPS because it significantly
increases morbidity (hypertension, diabetes, preterm births) without
any demonstrable benefit
•Immunoglobulin therapy is experimental and not for clinical use at
present
What not to do for PAPS
Antiphospholipid Syndrome: Intravenous
Immunoglobulin therapy
Triolo G, et al. Arthritis Rheum 2003:
Low-molecular-weight heparin + aspirin - Higher rate of live births
than those treated with intravenous immunoglobulin (RR 2.28)
Dendrinos S et al. Int J Gynaecol Obstet 2009:
Low-molecular-weight heparin + aspirin resulted in a higher live birth
rate than intravenous immunoglobulin (OR 1.80)
https://www.rcog.org.uk/globalassets/documents/guidelines/gtg_17.pdf
Anatomical Factors
Uterine anomalies : How Common ?
General population 6.3%
Infertile women 7.6%
Women with reproductive failure 16.1%
Saravelos H et al, Hum Rep Update 2008
Which anomaly ?
General Infertile Recurrent
Miscarriage
Hypoplastic 0 0.7 0
Unicornuate 0.03 0.4 0.4
Didelphys 0.03 0.2 0.1
Bicornuate 0.3 0.8 1
Septate 2 3.5 5
Arcuate 4.9 1.9 12.2
T shaped 0 0 0.6
Saravelos H et al, Hum Rep Update 2008
Uterine anomalies
Most common anomaly is a septate or subseptate
uterus
Others: T-shaped uterus, fibroids, intrauterine
adhesions
Jurkovic D et al, BJOG 1997
Possible Mechanisms
Small cavity, less suitable areas for implantation
Vascular compromise
Mechanical constraints of space
Cervical incompetence
Diagnosis of uterine anomalies
Hysteroscopy with laparoscopy is the gold standard
Sonosalpingography and 3D ultrasound have more than
90% accuracy
Hysteroscopy is the only one which allows a “see-and-
treat” approach
Key points-anatomical factors
RPL may be due to anatomical causes
Hysteroscopic surgery is the modality of choice for treating
most cases
Postoperative measures to prevent intrauterine adhesion
formation should be taken
Anatomical causes are a potentially rewarding etiology to
diagnose and treat
Cervical
Insufficiency
Cervix
Most neglected part of obstetric sonography !!
Incidence
It is estimated that cervical incompetence will complicate
anywhere from 0.5% to 2% of all pregnancies
CI is responsible for approximately 15% of habitual
immature deliveries between 16 and 28 weeks of gestation
Etiology
Idiopathic -In most cases
Known causes include
- Congenital weakness as Mullerian abnormalities (cervical hypoplasia)
 -In utero DES (diethylstilbestrol) exposure
 -Traumatic abnormalities (prior surgical or obstetric trauma)
 -Connective tissue abnormalities (Ehlers-Danlos syndrome).
DIAGNOSIS OF CI
History of painless repeated mid trimester spontaneous
miscarriage or premature delivery
Manual estimations
Ability to introduce a number 8 Hegar dilator through the
internal os when patient is not pregnant.
Hysterosalpingogram demonstrating cervical funneling.
Clinical evidence of extensive obstetric or surgical trauma to
cervix.
Transabdominal Sonography
Fails to visualise the cervix in a high
proportion of cases and in particular those
with a short cervix.
Successful visualisation requires a full
bladder which falsely increases cervical
length.
The best approach for
measurement of cervical length is
by Transvaginal Sonography.
Technique
1. Empties her bladder
2. Lithotomy position.
3. The ultrasound probe is introduced in the vagina and directed in the
anterior fornix.
4. Avoid undue pressure on the cervix, which may artificially increase
the length.
5. A sagittal view of the cervix is obtained and the endocervical mucosa
is used as a guide to the true position of the internal os.
Transvaginal Sonography
Sonographic criteria for Cervical incompetence
1. Cervical length shortening to a length below 5th centile
(20 mms) before 24 weeks
1. Funneling of the internal os at least 30% of the total
length of cervix - (funnel + residual length), observed
spontaneously or after Fundal pressure
--the shorter the cervix ,
--the earlier in gestational age at which the shortening
occurs,
Higher the risk.
--
Key Points
Circlage-Elective
Emergency cerclage
Reserved for patients without classical features of
incompetence
Success rate lower
Higher incidence of infection
Prolonged hospital stay
Infective
Role of TORCH panel
No Role
Immunotherapy
Immunotherapy
Paternal cell immunisation, third-party donor leucocytes,
trophoblast membranes and intravenous immunoglobulin in women
with previous unexplained recurrent miscarriage does not improve
the live birth rate.
Porter TF et al. Cochrane Database Syst Rev 2006:
◦ Provides no significant beneficial effect over placebo in preventing
further miscarriage
Harrison RF. Eur J Obstet Gynecol Reprod Biol 1992;47:175–9.
Quenby S, Farquharson RGFertil Steril 1994;62:708–10.
Inherited Thrombophilias
Inherited thrombophilias
Insufficient evidence to evaluate effect of heparin in pregnancy to
prevent miscarriage in women with recurrent first-trimester
miscarriage associated with inherited thrombophilia
Heparin therapy during pregnancy may improve live birth rate of
women with second-trimester miscarriage associated with inherited
thrombophilias
Harrison RF. Eur J Obstet Gynecol Reprod Biol 1992;47:175–9.
Quenby S, Farquharson RGFertil Steril 1994;62:708–10.
Endocrine Factors
Endocrinal factors
Luteal phase defects
Thyroid replacement therapy
Optimizing HBA1c levels
Correct hyperprolactinaemia
Polycystic ovaries ? metformin
What are the available guidelines
for Use of Progestogens in RM ?
FOGSI - Good Clinical Practice Recommendations: Use of Progestogens in
Early Pregnancy
Recurrent Miscarriage
• Dydrogesterone: 10 mg BD till 20 weeks of pregnancy
http://www.fogsi.org/fogsi-gcpr/. Accessed on 12th Jan 2016
Oral Route
Vaginal Route
• Micronized Progesterone: 400 mg/day vaginally till 20
weeks of pregnancy
How to Choose Progestogens?
The Patient’s choice ?The Doctor’s Choice ?
Doctor’s Choice
•Evidence based
•Efficacy
•Safety & Side effects
•Results
Patient’s Choice
Convenience
Ease
Cost
Result
What is the safety aspect of
Progestogens Use in RM?
FOGSI - Good Clinical Practice Recommendations: Use of Progestogens in
Early Pregnancy
Safety of Progestogens
Available evidence strongly supports safety of progesterone when used in pregnancy (based on
available clinical data on vaginal progesterone & dydrogesterone)
http://www.fogsi.org/fogsi-gcpr/. Accessed on 12th Jan 2016
FOGSI - Good Clinical Practice Recommendations: Use of Progestogens in
Early Pregnancy
Safety of Progestogens
Progesterone should be used with caution in patients with cardiovascular diseases & in patients
with impaired liver function & cholestasis
http://www.fogsi.org/fogsi-gcpr/. Accessed on 12th Jan 2016
Dydrogesterone vs. Micronized
Progesterone
Dydrogesterone Compared with Micronized Progesterone
Selective for the progesterone receptor (and thus avoiding other receptor related side-effects)1-3
Dydrogesterone vs oral micronized progesterone
◦ Better oral bioavailability1,2
◦ Requires a 10–20 times lower oral dose1,2
Oral micronized progesterone is associated with a risk of cholestasis in pregnancy4
Vaginal micronized progesterone is also metabolized in the liver5
These differences translate into clinical benefits6-8
1.Schindler AE, et al. Maturitas. 2008; 61(1-2):171-180. 2. Schindler AE. Maturitas 2009; 65S: S3-S11.
3. Rižner TL, et al. Steroids. 2011;76(6):607-615; 4. Utrogestan 200mg oral capsules. SPC. UK October 2013;
5.. Utrogestan 200mg vaginal capsules. SPC. UK October 2013; 6. Patki A, et al. Gynecol Endocrinol. 2007; 23(Suppl 1): 68-726;
7. Ganesh A, et al. Fertility and Sterility. 2011;95(6):1961-1965. 8. Chakravarty BN, et al. J Steroid Biochem Mol Biol. 2005; 97(5):416-420.
Genetic Factors
Mostly sporadic ; 80% losses in 1st 12 wks
50-70% due to chromosomal anomalies
◦ Autosomal trisomy 50-60%
◦ 13,16,18,21,others
◦ Monosomy X-20%
◦ Triploidy –15%
◦ Tetraploidy-5%
◦ balanced translocation-3-5%
Spontaneous Miscarriage
Parental Karyotypes normal Minimal recurrence risk
Karyotype of the abortus
( fetal/placental tissue)
Peripheral blood Karyotyping of the parents in all couples
with RM
Whether we should do POC
karyotype????
 No definite recommendations for routinely
obtaining abortus karyotype (ACOG 2001)
 Karyotype analysis of abortus tissue for couples with a subsequent
second or third pregnancy loss (Hogge, et al 2003)
 If abortus is aneuploid, maternal cause is excluded (ACOG, 2001)
 If POC karyotype not possible, do parental karyotype
Normal
Abnormal (trisomy or chromosomal rearrangement)
Both requires parental karyotype
Direct parental karyotype is more cost effective
Genetic
Fetal POC
Karyotype
Euploid-
RPL
workup
Unbalanced
translocation or
inversion-Parental
Karyotype ,offer
PGD
Aneuploid-No
further
evaluation,
consider PGD
Side Effects to Embryo
PGD/PGS is an invasive procedure that requires a serious consideration,
One of the risks of PGD includes damage to the embryo during the biopsy
procedure (which in turn destroys the embryo as a whole)
Another risk is cryopreservation where the embryo is stored in a frozen state
and thawed later for the procedure.
About 20% of the thawed embryos do not survive.[31][32]
 There has been a study indicating a biopsied embryo has a less rate of surviving
cryopreservation.
"Reduced survival after human embryo biopsy and subsequent cryopreservation".
Human Reproduction vol.14 no.11 pp.2833-2837.
Ethical issues
The technique can be used for prenatal sex discernment of the embryo, and
thus potentially can be used to select embryos of one sex in preference of the
other in the context of "family balancing".
PGD allows discrimination against those with disabilities
PGD has the potential to screen for genetic issues unrelated to medical
necessity such as intelligence and beauty, and against negative traits such as
disabilities.
The prospect of a "designer baby" is closely related to the PGD technique,
creating a fear that increasing frequency of genetic screening will move toward a
modern eugenics movement.
Policy and legality
In India, Ministry of Family Health and Welfare, regulates the concept under -
"The Pre-Conception and Prenatal Diagnostic Techniques (Prohibition of Sex
Selection) Act, 1994".
The Act was further been revised after 1994 and necessary amendment were
made are updated timely on the official website of the Indian Government
dedicated for the cause.
ahttp://www.pndt.gov.in/
Unexplained Recurrent
Miscarriage
Unexplained Recurrent Miscarriage
Aspirin alone or in combination with heparin is being prescribed
for women with unexplained RM, with the aim of improving
pregnancy outcome
◦ 2 RCTs reported that neither of these interventions improves
live birth rate among women with unexplained RM
https://www.rcog.org.uk/globalassets/documents/guidelines/gtg_17.pdf
Unexplained RPL
50% of RPL remain unexplained
Prognosis is still good
◦>50 % live birth even without intervention
Unexplained RPL - Pregnancy Issues
Increased risk of :
○IUGR
○Preterm labor
No increased risk of:
○PIH
○GDM
TLC
Tender Loving Care
Conclusion
RPL is an important reproductive health issue. Various etiologies have identified
over the years and successful therapeutic strategies implemented.
A full workup can be initiated following two consecutive losses to identify
treatable causes that include uterine abnormalities, APS, endocrine diseases,
and balanced translocations.
Lifestyle modifications should also be implemented to improve reproductive
prognosis. However, almost half of the cases remain unexplained, for which
various treatments are continuously being developed.
Regardless of the cause, a thorough follow up with an important psychological
support can help most couples achieve a successful live birth
Dr. Laxmi Shrikhande
Shrikhande Hospital & research Centre
Ph-96234 59766 / shrikhandedrlaxmi@gmail.com

Recurrent pregnancy loss

  • 1.
    Dr. LaxmiShrikhande MD;FICOG;FICMU Director-Shrikhande FertilityClinic, Nagpur President Menopause Society, Nagpur National Corresponding Editor-The Journal of Obstetrics & Gynecology of India Senior Vice President FOGSI 2012 Vice Chairperson Indian College OB /GY Governing Council member ICOG 2012-2017 Governing Council Member ISAR 2014-2019 Governing Council Member IAGE for 3 terms Patron-Vidarbha Chapter ISOPARB Chairperson-HIV/AIDS Committee, FOGSI (2007-09) Received Best Committee Award of FOGSI Received Bharat excellence Award for women’s health President Nagpur OB/GY Society 2005-06 Associate member of RCOG Member of European Society of Human Reproduction Visited 96 FOGSI Societies as invited faculty Delivered 3 orations Publications-Thirteen National & seven International Presented Papers in FIGO, AICOG, SAFOG, AICC-RCOG conferences Conducted adolescent health programme for more than 15,000 adolescent girls
  • 2.
    Recurrent Pregnancy loss DRLAXMI SHRIKHANDE NAGPUR
  • 3.
    Introduction Emotionally traumatic, similarto stillbirth or neonatal death Primary / secondary / Tertiary Primary RPL- refers to multiple losses in a woman with no previous viable infants, secondary RPL refers to multiple losses in a woman who has already had a pregnancy beyond 20 gestational weeks Tertiary RPL refers to multiple pregnancy losses between normal pregnancies ◦Better prognosis with secondary and Tertiary Terminology for pregnancy loss prior to viability : a consensus statement from the ESHRE early pregnancy special interest group. Hum Reprod 2015;30(3):495-498 Nomenclature for pregnancy outcomes : time for a change. Obstet Gynecol 2011 ; 118(6): 1402-1408
  • 4.
    RPL – basicfacts 1% of women have recurrent miscarriages A majority of women do not have an identifiable cause At least 70% of women have a successful pregnancy outcome in the subsequent pregnancy ACOG Practice Bulletin No.24, 2001 RCOG GreenTop Guideline No.17, 2003
  • 5.
    Why is studyingRPL difficult? More than one factor may exist in the same couple Lacunae in literature ◦ Differences in definitions, evaluation protocols ◦ Variations in treatment regimens even with the same drug ◦ Randomized trials need to be very large to prove statistical and clinically significant differences
  • 6.
    Women with H/O2 previous spontaneous abortions Has come for preconception counselling Will you start investigating ?
  • 7.
    Recurrent Miscarriage Recurrent MiscarriageDefinitions ◦ 3 or more consecutive pregnancy losses (UK)1 ◦ 2 or more consecutive pregnancy losses (USA)2 ◦ Miscarriage as loss of fetus weighing ≤ 500g, which would normally be at 20-22 complete weeks of gestation (WHO)3 1. Royal College of Obstetricians and Gynaecologists 2011. The Investigation and Treatment of Couples with Recurrent First-trimester and Second-trimester Miscarriage, [Guideline no. 17]. London, UK. 2. 2. Practice Committee of the American Society for Reproductive Medicine. Fertil Steril 2008; 90(5 Suppl): S60. 3. 3. Pokale YS. Int. Res. J. Medical Sci. 2015;3(9):13-19
  • 8.
    How you willproceed further ?
  • 9.
    Diagnostic Work-Up inRecurrent Miscarriage?
  • 10.
    Pathogenesis & DiagnosticWork-Up in Recurrent Miscarriage (RM) Heterogeneous condition Pathogenesis is multifactorial, complex and poorly understood Standard investigative protocol fails to identify specific cause in 50% of cases Walch KT & Huber JC. Best Practice & Research Clinical Obstetrics and Gynaecology. 2008; Vol. 22, No. 2, pp. 375–389. Pokale YS. Int. Res. J. Medical Sci. 2015;3(9):13-19
  • 11.
    What are thepossible causes of RPL
  • 12.
    Possible Causes ofMiscarriage Paternal Factor Abnormal embryo  Structural anomalies incompatible with life1  Chromosomal abnormalities: trisomy, polyploidy, monosomy X, structural abnormalities of individual chromosomes2 Hostile maternal environment  Uterine abnormalities: congenital anomalies, adhesions, leiomyoma2  Infection: bacterial vaginosis, toxoplasmosis, listeriosis, chlamydia, gonorrhea, rubella2  Chronic maternal disease: poorly controlled diabetes, celiac disease2  Immune dysfunction: antiphospholipid antibody syndrome2 and thyroid autoimmunity1  Endocrine: failure of proper progesterone concentration, thyroid hormone levels3 1. Larsen EC et al. BMC Medicine 2013; 11: 154-65. 2. Griebel CP et al. Am Fam Physician 2005;1; 72(7): 1243-50.3. Zhang HX et al. Clin Exp Obstet Gynecol 2014; 41(2): 182-5.
  • 13.
    Etiology Established causes ofrecurrent miscarriage include  immunological (20-50%), endocrine (17-20%), anatomical (12-16%), genetic (5%), and infection (0.5-1.5%).
  • 14.
    Evaluation It includes taking history, physicalexamination and appropriate investigations which differ with the trimester though there is an overlap.1 1) Evaluation and management of recurrent early pregnancy loss. Stephenson M, Kutteh W.Clin Obstet Gynecol. 2007 Mar;50(1):132-45.
  • 15.
    History Gestational age ofthe loss. Chromosomal & endocrine earlier than anatomic or immunological causes Irregular menstrual cycles or galactorrhoea suggestive of possible Endocrine dysfunction/ Hyperprolactinemia Consanguinity/ family h/o congenital abnormalities/early losses - Genetic Uterine instrumentation- possible intrauterine adhesions Exposure to exogenous agents like bisphenol A and concurrent noxious agents is difficult to recall, document and to measure the toxin dose. Radiation and Chemotherapeutic agents, chemicals. Alcohol and caffeine intake are toxic to the embryo in a dose-dependent manner. Cigarette smoking, H/o thrombosis - APLA PCOS Information from previous laboratory, pathology, and imaging studies
  • 16.
    Examination General-Signs of endocrinopathy(hirsutism, galactorrhea, thyroid) Systemic Gynec TVS
  • 17.
    Which tests toorder ? Eyes can’t see what mind doesn’t know From History and examination you should draw your further course of action
  • 18.
    Investigations recommended forrecurrent miscarriages Investigation Recommendation If required Genetic - Karyotype Parental and fetal Anatomical Two-dimensional/ three-dimensional ultrasonography and sonohysterography Hysteroscopy, laparoscopy, or magnetic resonance imaging Thrombophilia Acquired APS Inherited Infection Chlamydia, Endometrial biopsy and culture Immunological Antinuclear antibody Endocrine Thyroid -TSH, Antibodies Prolactin,HbA1C Male factor Sperm DNA fragmentation index
  • 19.
    Male factor- Some studiessuggest that DNA fragmentation is increased with RPL, especially in the in vitro fertilization setting. The ASRM guidelines state that routine sperm DNA fragmentation indexing is not indicated because of the weak evidence, but  the ESHRE guidelines state that this can be done to provide an explanation for RPL.
  • 20.
    Evidence Further compelling reasonsfor testing sperm DNA come from its strong associations with miscarriage. A systematic review and meta-analysis (16) of 16 cohort studies (2969 couples), 14 of which were prospective studies which examined the effect of sperm DNA damage on miscarriage rates was performed. The meta-analysis showed a significant increase in miscarriage in patients with high DNA damage compared with those with low DNA damage (Risk Ratio (RR)= 2.16 [1.54, 3.03], P <0.00001).
  • 21.
    Recurrent Miscarriage-Maternal causes RecommendedInvestigations to Search for Causes (UK)1 1. Royal College of Obstetricians and Gynaecologists 2011. The Investigation and Treatment of Couples with Recurrent First-trimester and Second-trimester Miscarriage, [Guideline no. 17]. London, UK. Antiphospholipid antibodies Karyotyping Anatomical factors Thrombophilias
  • 22.
  • 23.
    A number ofantibodies have been studied The antibodies with the greatest significance and association with obstetric events are Lupus anticoagulant (LA) Anticardiolipin antibodies (ACL IgG and ACL IgM) Others such as β2glycoprotein-I, antiphosphatidylserine antibodies, annexin, etc may not be obstetrically significant Which antibodies ?
  • 24.
    •5 – 20%of women with recurrent miscarriages have antiphospholipid antibodies MacLean AS et al, BJOG 1994 Rai RS et al, Hum Reproduction 1995 Balasch J et al, Hum Reproduction 1996 Incidence
  • 25.
    How you willdiagnose APS ?
  • 26.
    •Based on clinicaland laboratory criteria •One obstetric or thrombotic criteria and one laboratory criteria should be present to diagnose PAPS •Other autoimmune disease has to be ruled out to make the diagnosis of PAPS Wilson A et al, International Consensus statement on APS, Arthritis Rheumatol 1999 Diagnosis of PAPS
  • 27.
    Three or moreconsecutive spontaneous abortion before the 10th week of gestation One or more unexplained fetal death at or beyond the 10th week of gestation Severe preeclampsia or placental insufficiency (IUGR) necessitating birth before the 34th week of gestation Obstetric Criteria
  • 28.
    •Anticardiolipin antibody IgGor IgM isotype in medium to high titers by standardized ELISA assay •Lupus anticoagulant present •A positive test has to be repeated on at least one more occasion six weeks apart to fulfill the laboratory criteria Laboratory Criteria
  • 29.
    Usually an overdiagnosed syndrome Not meeting clinical and the strict laboratory criteria Not repeating the laboratory test at 6 weeks Non standardized ELISA for ACL antibodies Inter laboratory variations for phospholipid dependent coagulation tests used for screening for lupus anticoagulant Pitfalls in diagnosis of PAPS
  • 30.
    Improperly collected andprocessed samples Temporal and trimester wise fluctuations VDRL positive patients who may or may not have syphilis General infections and inflammations Coagulopathies and anticoagulant medication users (including aspirin, heparin) False results in PAPS
  • 31.
  • 32.
    Avoid early pregnancyloss Normalize placental and fetal circulations to prevent early birth from obstetric complications such as preeclampsia and growth restriction Prevent maternal vascular thrombosis in pregnancy and postpartum Goals for treating PAPS
  • 33.
    Women with PAPS withouta history of thrombotic events (most women with RPL) Women with PAPS with history of thrombotic events (past or present) Prophylactic therapies such as aspirin, heparin in pregnancy and 6 to 8 weeks postpartum Full anticoagulation with heparin (or warfarin) in pregnancy and postpartum
  • 34.
    Recent meta analysisshows that the combination of Aspirin + Heparin is better than Aspirin alone in achieving live births in women with recurrent pregnancy loss and antiphospholipid antibodies Aspirin alone v/s Aspirin + Heparin Mak A et al, Rheumatology (Oxford) 2010
  • 35.
    How to useheparin ?
  • 36.
    •There is controversyas to whether LMW Heparin is effective in preventing recurrent pregnancy loss •Consider costs, convenience and compliance before initiating therapy •Therapy should be started when fetal cardiac activity is demonstrated and continued throughout pregnancy and postpartum •Heparin in prophylactic doses needs to be stopped for about 24 hours around the time of labor and delivery Clinical Tips for using Heparin
  • 37.
    Heparin in prophylacticdoses should not be monitored and does not require monitoring by coagulation parameters Do a platelet count at 3 days, 1 week and bimonthly when the patient is on heparin Standard doses Unfractionated heparin – 5000 units sc bd Enoxaparin – 40 mg sc daily or in two doses Clinical Tips for using Heparin
  • 38.
    What not todo for PAPS
  • 39.
    •Steroid therapy shouldbe avoided for PAPS because it significantly increases morbidity (hypertension, diabetes, preterm births) without any demonstrable benefit •Immunoglobulin therapy is experimental and not for clinical use at present What not to do for PAPS
  • 40.
    Antiphospholipid Syndrome: Intravenous Immunoglobulintherapy Triolo G, et al. Arthritis Rheum 2003: Low-molecular-weight heparin + aspirin - Higher rate of live births than those treated with intravenous immunoglobulin (RR 2.28) Dendrinos S et al. Int J Gynaecol Obstet 2009: Low-molecular-weight heparin + aspirin resulted in a higher live birth rate than intravenous immunoglobulin (OR 1.80) https://www.rcog.org.uk/globalassets/documents/guidelines/gtg_17.pdf
  • 41.
  • 42.
    Uterine anomalies :How Common ? General population 6.3% Infertile women 7.6% Women with reproductive failure 16.1% Saravelos H et al, Hum Rep Update 2008
  • 43.
    Which anomaly ? GeneralInfertile Recurrent Miscarriage Hypoplastic 0 0.7 0 Unicornuate 0.03 0.4 0.4 Didelphys 0.03 0.2 0.1 Bicornuate 0.3 0.8 1 Septate 2 3.5 5 Arcuate 4.9 1.9 12.2 T shaped 0 0 0.6 Saravelos H et al, Hum Rep Update 2008
  • 44.
    Uterine anomalies Most commonanomaly is a septate or subseptate uterus Others: T-shaped uterus, fibroids, intrauterine adhesions Jurkovic D et al, BJOG 1997
  • 45.
    Possible Mechanisms Small cavity,less suitable areas for implantation Vascular compromise Mechanical constraints of space Cervical incompetence
  • 46.
    Diagnosis of uterineanomalies Hysteroscopy with laparoscopy is the gold standard Sonosalpingography and 3D ultrasound have more than 90% accuracy Hysteroscopy is the only one which allows a “see-and- treat” approach
  • 47.
    Key points-anatomical factors RPLmay be due to anatomical causes Hysteroscopic surgery is the modality of choice for treating most cases Postoperative measures to prevent intrauterine adhesion formation should be taken Anatomical causes are a potentially rewarding etiology to diagnose and treat
  • 48.
  • 49.
    Cervix Most neglected partof obstetric sonography !!
  • 50.
    Incidence It is estimatedthat cervical incompetence will complicate anywhere from 0.5% to 2% of all pregnancies CI is responsible for approximately 15% of habitual immature deliveries between 16 and 28 weeks of gestation
  • 51.
    Etiology Idiopathic -In mostcases Known causes include - Congenital weakness as Mullerian abnormalities (cervical hypoplasia)  -In utero DES (diethylstilbestrol) exposure  -Traumatic abnormalities (prior surgical or obstetric trauma)  -Connective tissue abnormalities (Ehlers-Danlos syndrome).
  • 52.
    DIAGNOSIS OF CI Historyof painless repeated mid trimester spontaneous miscarriage or premature delivery Manual estimations Ability to introduce a number 8 Hegar dilator through the internal os when patient is not pregnant. Hysterosalpingogram demonstrating cervical funneling. Clinical evidence of extensive obstetric or surgical trauma to cervix.
  • 53.
    Transabdominal Sonography Fails tovisualise the cervix in a high proportion of cases and in particular those with a short cervix. Successful visualisation requires a full bladder which falsely increases cervical length.
  • 54.
    The best approachfor measurement of cervical length is by Transvaginal Sonography. Technique
  • 55.
    1. Empties herbladder 2. Lithotomy position. 3. The ultrasound probe is introduced in the vagina and directed in the anterior fornix. 4. Avoid undue pressure on the cervix, which may artificially increase the length. 5. A sagittal view of the cervix is obtained and the endocervical mucosa is used as a guide to the true position of the internal os. Transvaginal Sonography
  • 56.
    Sonographic criteria forCervical incompetence 1. Cervical length shortening to a length below 5th centile (20 mms) before 24 weeks 1. Funneling of the internal os at least 30% of the total length of cervix - (funnel + residual length), observed spontaneously or after Fundal pressure
  • 57.
    --the shorter thecervix , --the earlier in gestational age at which the shortening occurs, Higher the risk. -- Key Points
  • 58.
  • 59.
    Emergency cerclage Reserved forpatients without classical features of incompetence Success rate lower Higher incidence of infection Prolonged hospital stay
  • 60.
  • 61.
    Role of TORCHpanel No Role
  • 62.
  • 63.
    Immunotherapy Paternal cell immunisation,third-party donor leucocytes, trophoblast membranes and intravenous immunoglobulin in women with previous unexplained recurrent miscarriage does not improve the live birth rate. Porter TF et al. Cochrane Database Syst Rev 2006: ◦ Provides no significant beneficial effect over placebo in preventing further miscarriage Harrison RF. Eur J Obstet Gynecol Reprod Biol 1992;47:175–9. Quenby S, Farquharson RGFertil Steril 1994;62:708–10.
  • 64.
  • 65.
    Inherited thrombophilias Insufficient evidenceto evaluate effect of heparin in pregnancy to prevent miscarriage in women with recurrent first-trimester miscarriage associated with inherited thrombophilia Heparin therapy during pregnancy may improve live birth rate of women with second-trimester miscarriage associated with inherited thrombophilias Harrison RF. Eur J Obstet Gynecol Reprod Biol 1992;47:175–9. Quenby S, Farquharson RGFertil Steril 1994;62:708–10.
  • 66.
  • 67.
    Endocrinal factors Luteal phasedefects Thyroid replacement therapy Optimizing HBA1c levels Correct hyperprolactinaemia Polycystic ovaries ? metformin
  • 68.
    What are theavailable guidelines for Use of Progestogens in RM ?
  • 69.
    FOGSI - GoodClinical Practice Recommendations: Use of Progestogens in Early Pregnancy Recurrent Miscarriage • Dydrogesterone: 10 mg BD till 20 weeks of pregnancy http://www.fogsi.org/fogsi-gcpr/. Accessed on 12th Jan 2016 Oral Route Vaginal Route • Micronized Progesterone: 400 mg/day vaginally till 20 weeks of pregnancy
  • 70.
    How to ChooseProgestogens? The Patient’s choice ?The Doctor’s Choice ?
  • 71.
  • 72.
  • 73.
    What is thesafety aspect of Progestogens Use in RM?
  • 74.
    FOGSI - GoodClinical Practice Recommendations: Use of Progestogens in Early Pregnancy Safety of Progestogens Available evidence strongly supports safety of progesterone when used in pregnancy (based on available clinical data on vaginal progesterone & dydrogesterone) http://www.fogsi.org/fogsi-gcpr/. Accessed on 12th Jan 2016
  • 75.
    FOGSI - GoodClinical Practice Recommendations: Use of Progestogens in Early Pregnancy Safety of Progestogens Progesterone should be used with caution in patients with cardiovascular diseases & in patients with impaired liver function & cholestasis http://www.fogsi.org/fogsi-gcpr/. Accessed on 12th Jan 2016
  • 76.
    Dydrogesterone vs. Micronized Progesterone DydrogesteroneCompared with Micronized Progesterone Selective for the progesterone receptor (and thus avoiding other receptor related side-effects)1-3 Dydrogesterone vs oral micronized progesterone ◦ Better oral bioavailability1,2 ◦ Requires a 10–20 times lower oral dose1,2 Oral micronized progesterone is associated with a risk of cholestasis in pregnancy4 Vaginal micronized progesterone is also metabolized in the liver5 These differences translate into clinical benefits6-8 1.Schindler AE, et al. Maturitas. 2008; 61(1-2):171-180. 2. Schindler AE. Maturitas 2009; 65S: S3-S11. 3. Rižner TL, et al. Steroids. 2011;76(6):607-615; 4. Utrogestan 200mg oral capsules. SPC. UK October 2013; 5.. Utrogestan 200mg vaginal capsules. SPC. UK October 2013; 6. Patki A, et al. Gynecol Endocrinol. 2007; 23(Suppl 1): 68-726; 7. Ganesh A, et al. Fertility and Sterility. 2011;95(6):1961-1965. 8. Chakravarty BN, et al. J Steroid Biochem Mol Biol. 2005; 97(5):416-420.
  • 77.
  • 78.
    Mostly sporadic ;80% losses in 1st 12 wks 50-70% due to chromosomal anomalies ◦ Autosomal trisomy 50-60% ◦ 13,16,18,21,others ◦ Monosomy X-20% ◦ Triploidy –15% ◦ Tetraploidy-5% ◦ balanced translocation-3-5% Spontaneous Miscarriage Parental Karyotypes normal Minimal recurrence risk
  • 79.
    Karyotype of theabortus ( fetal/placental tissue) Peripheral blood Karyotyping of the parents in all couples with RM
  • 80.
    Whether we shoulddo POC karyotype????
  • 81.
     No definiterecommendations for routinely obtaining abortus karyotype (ACOG 2001)  Karyotype analysis of abortus tissue for couples with a subsequent second or third pregnancy loss (Hogge, et al 2003)  If abortus is aneuploid, maternal cause is excluded (ACOG, 2001)  If POC karyotype not possible, do parental karyotype
  • 82.
    Normal Abnormal (trisomy orchromosomal rearrangement) Both requires parental karyotype Direct parental karyotype is more cost effective
  • 83.
  • 84.
    Side Effects toEmbryo PGD/PGS is an invasive procedure that requires a serious consideration, One of the risks of PGD includes damage to the embryo during the biopsy procedure (which in turn destroys the embryo as a whole) Another risk is cryopreservation where the embryo is stored in a frozen state and thawed later for the procedure. About 20% of the thawed embryos do not survive.[31][32]  There has been a study indicating a biopsied embryo has a less rate of surviving cryopreservation. "Reduced survival after human embryo biopsy and subsequent cryopreservation". Human Reproduction vol.14 no.11 pp.2833-2837.
  • 85.
    Ethical issues The techniquecan be used for prenatal sex discernment of the embryo, and thus potentially can be used to select embryos of one sex in preference of the other in the context of "family balancing". PGD allows discrimination against those with disabilities PGD has the potential to screen for genetic issues unrelated to medical necessity such as intelligence and beauty, and against negative traits such as disabilities. The prospect of a "designer baby" is closely related to the PGD technique, creating a fear that increasing frequency of genetic screening will move toward a modern eugenics movement.
  • 86.
    Policy and legality InIndia, Ministry of Family Health and Welfare, regulates the concept under - "The Pre-Conception and Prenatal Diagnostic Techniques (Prohibition of Sex Selection) Act, 1994". The Act was further been revised after 1994 and necessary amendment were made are updated timely on the official website of the Indian Government dedicated for the cause. ahttp://www.pndt.gov.in/
  • 87.
  • 88.
    Unexplained Recurrent Miscarriage Aspirinalone or in combination with heparin is being prescribed for women with unexplained RM, with the aim of improving pregnancy outcome ◦ 2 RCTs reported that neither of these interventions improves live birth rate among women with unexplained RM https://www.rcog.org.uk/globalassets/documents/guidelines/gtg_17.pdf
  • 89.
    Unexplained RPL 50% ofRPL remain unexplained Prognosis is still good ◦>50 % live birth even without intervention
  • 90.
    Unexplained RPL -Pregnancy Issues Increased risk of : ○IUGR ○Preterm labor No increased risk of: ○PIH ○GDM
  • 91.
  • 92.
    Conclusion RPL is animportant reproductive health issue. Various etiologies have identified over the years and successful therapeutic strategies implemented. A full workup can be initiated following two consecutive losses to identify treatable causes that include uterine abnormalities, APS, endocrine diseases, and balanced translocations. Lifestyle modifications should also be implemented to improve reproductive prognosis. However, almost half of the cases remain unexplained, for which various treatments are continuously being developed. Regardless of the cause, a thorough follow up with an important psychological support can help most couples achieve a successful live birth
  • 93.
    Dr. Laxmi Shrikhande ShrikhandeHospital & research Centre Ph-96234 59766 / [email protected]